Hyperlipidemia: Are the PCSK9 inhibitors bouncing back?
This article, published by Pharma Times May 2019, considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.
The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products in multiple markets. These obstacles partly reflect initial premium pricing of the two available PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab). Price differentials have been all the more marked given the established reliability of low-cost, genericised statins as a tool for lowering cholesterol. In that light, many physicians, thought leaders and payers opted to wait for persuasive outcomes data that would substantiate the ability of the PCSK9 inhibitors to offset higher costs with long-term gains in preventing mortality, hospitalisation or other serious cardiovascular events.
How a two-phase evaluation involving interactive workshops gave guidance for improving a Patient Assistance Programme in CV
Our client had launched a self-injection treatment for cardiovascular conditions and were creating an accompanying Patient Assistance Programme (PAP) to educate patients in the use and uptake of this product. The client wanted to understand how successful the PAP was at meeting the needs of patients, trainers and prescribers, and whether it positively differentiated them from competitors. They wanted to evaluate each individual component of the PAP (e.g. brochures, website, videos, training kits, patient emails), the clarity of each component and their usefulness across the patient journey. They also wanted to identify any gaps or needs for improvement in the PAP.
Qualitative research with payers in low and middle income countries
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in low and middle income countries where patients self-pay for healthcare.
They also wanted to obtain a deep understanding of the groups of patients for whom self-pay is an issue and the sources of public funding that could potentially be leveraged. Our findings would complement market access considerations and point the way forward to a self-pay strategy that would maximise the potential for our client’s product.